Navigation Links
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Date:6/1/2009

A has not been formally studied in patients with CHF. Exercise caution when using CIMZIA in patients who have heart failure and monitor them carefully.

Symptoms compatible with hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria, have been reported rarely following CIMZIA administration. If such reactions occur, discontinue further administration of CIMZIA and institute appropriate therapy.

Use of TNF blockers, including CIMZIA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal. Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating CIMZIA therapy. Exercise caution in prescribing CIMZIA for patients identified as carriers of HBV. Patients who are carriers of HBV and require treatment with CIMZIA should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, discontinue CIMZIA and initiate effective anti-viral therapy with appropriate supportive treatment.

Use of TNF blockers, including CIMZIA, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA; the causal relationship to CIMZIA remains unclear. Exercise caution in considering the use of CIMZIA in patients with these disorders.

Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) has been infrequently reported with CIMZIA. The causal relationship of the
'/>"/>

SOURCE UCB, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
2. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
3. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
4. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
5. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
6. Resverlogix Provides Quarterly Update
7. China Sky One Medical, Inc. Provides Update on Filing Form 10-K
8. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
9. US Oncology Provides Full Service Management of Clinical Trials
10. SemBioSys provides update on insulin program
11. Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... ... managed with the use of special anti-vascular endothelial growth factor agents given by ... patients, currently does not have a scientific protocol for the many millions diagnosed ...
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... ENGLEWOOD, Colo. , Sept. 2, 2015 ... focused on developing treatments for urological and related conditions, ... of its planned private placement convertible note financing, raising ... two prior tranches totaling $3.175 million. ... stated, "Proceeds from this private placement are intended to ...
(Date:9/2/2015)... 2, 2015 Biovista Inc. ... BeHEARD von 2015 bekanntgeben zu können. Hierbei handelt ... Institute. Biovista unterstützt mit seiner Möglichkeit ... Behandlung anderer Krankheiten als denen, für die ein ... und sein Team bei der Wylder Nation Foundation ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... Tolera,s Monoclonal Antibody Product Candidate -, ... Inc., a,full-service biopharmaceutical development and protein production ... a cGMP contract manufacturing,agreement with Tolera Therapeutics, ... targeted therapies and safer solutions for immune,modulation ...
... OSLO, Norway, October 28 Affitech AS, ... it had acquired the full,rights to the ... a leading Danish immunotherapeutic and vaccine company. ... are recombinant,antibody-like proteins whose unique attributes make ...
... Kits Offer Rapid, Robust Amplification of Partially ... Sigma-Aldrich (Nasdaq:,SIAL) today announced the launch ... ( http://www.sigma.com/wta ). TransPlex,technology is believed to ... method,available for amplifying total RNA from a ...
Cached Biology Technology:Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc. 2Affitech Acquires Pharmexa's Diabody Technology 2Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples 2
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... 31 juillet 2015 La 10e Conférence ... sera organisée par le BGI du 22 au ... en Chine. La conférence célèbre ... en 2006, l,ICG est devenue l,une des réunions ... des « omiques » et c,est aussi la plus dynamique, ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... Research and Markets ( http://www.researchandmarkets.com/research/7gqfnv/dna_microarray ) has ... A Focus on Sales Growth" report to their ... Microarray 2013 presents the findings of a global market ... buyers and end-users in this field. With a focus ...
... research team led by pediatric blood and marrow transplantation experts ... Masonic Cancer Center, University of Minnesota, have discovered a remarkable ... of patients with the skin disease epidermolysis bullosa. The ... and highlighted in the most recent issue of Nature ...
... mainstay of treatment for patients with end-stage liver disease, the ... new research from the Icahn School of Medicine at Mount ... today, suggests that it may one day become possible ... liver disease. Investigators discovered that a human embryonic stem cell ...
Cached Biology News:DNA Microarray 2013 Market Report: A Focus on Sales Growth 2U of M researchers find novel gene correction model for epidermolysis bullosa 2Mount Sinai discovers new liver cell for cellular therapy to aid in liver regeneration 2
... Protein G bind specifically to Fc regions ... Protein G conjugates are commonly used as ... immunoglobulin subtypes from serum, hybridoma ascites fluids, ... These reagents are also commonly used to ...
... instrument engineered to match the speed of ... of research centers worldwide. It uses 1.5 ... ideally suited for high-speed temperature cycling due ... surface-area-to-volume ratio. ,By combining glass capillary tubes ...
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
... LNA microarray slides for microRNA expression ... incorporate Exiqons unique Locked Nucleic Acid (LNA) ... mismatch discrimination for short microRNA (miRNA) targets. ... 1 g total RNA (no need for ...
Biology Products: